Biotechstockbot @biotechstockbot

@BioLineRx_Ltd reports 1Q *1st patient dosed in GLIX1 trial *Revs of $477k *Call @ 8:30 am ET $BLRX ir.biolinerx.com/news-releases/…

$BLRX Q1 2026 earnings: GLIX1 Enters the Clinic, but the H1 2027 Financing Clock is Ticking BioLineRx is now executing purely as a lean, clinical-stage oncology developer. The quarter's headline is the initiation of the GLIX1 Phase 1/2a trial in glioblastoma (GBM). With U. S. commercial operations for APHEXDA previously out-licensed to Ayrmid, revenues are now 100% royalty-driven ($0.5M this quarter). Consequently, the operating loss expanded to $3.0M as R&D spending accelerated to support the new trial. The primary tension for investors is the timeline: management guides for cash to last into H1 2027, which is the exact same window targeted for the GLIX1 clinical readout. This leaves essentially zero margin for clinical delays. Full article with charts - link in bio 🐂 𝐁𝐮𝐥𝐥 𝐂𝐚𝐬𝐞 • 𝐍𝐨𝐧-𝐃𝐢𝐥𝐮𝐭𝐢𝐯𝐞 𝐂𝐚𝐩𝐢𝐭𝐚𝐥 𝐒𝐭𝐫𝐞𝐚𝐦 𝐀𝐜𝐜𝐞𝐥𝐞𝐫𝐚𝐭𝐢𝐧𝐠 — APHEXDA sales by partner Ayrmid reached $2.7M in Q1 2026, up from $2.4M in Q3 2025 and $1.4M in Q1 2025. The resulting $0.5M royalty (an effective ~18.5% rate) provides pure-margin cash flow to partially offset R&D burn. • 𝐆𝐋𝐈𝐗𝟏 𝐏𝐫𝐞-𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐕𝐚𝐥𝐢𝐝𝐚𝐭𝐢𝐨𝐧 — Newly announced pre-clinical data demonstrated a robust anti-tumor effect in a temozolomide (TMZ)-resistant patient-derived xenograft model, highlighting GLIX1's potential to address massive unmet needs in GBM where standard of care has failed. 🐻 𝐁𝐞𝐚𝐫 𝐂𝐚𝐬𝐞 • 𝐓𝐡𝐞 𝐇𝟏 𝟐𝟎𝟐𝟕 𝐁𝐨𝐭𝐭𝐥𝐞𝐧𝐞𝐜𝐤 — The $17.4M cash runway extends into the first half of 2027. The GLIX1 Phase 1 data is also expected in H1 2027. This creates a critical financing bottleneck where the company may be forced to raise capital before having definitive, value-driving data in hand. • 𝐓𝐨𝐭𝐚𝐥 𝐑𝐞𝐥𝐢𝐚𝐧𝐜𝐞 𝐨𝐧 𝐏𝐚𝐫𝐭𝐧𝐞𝐫𝐬 — BioLineRx's near-term commercial revenue (APHEXDA) and secondary major clinical catalyst (PDAC Phase 2b trial) are entirely controlled by external partners (Ayrmid and Columbia University/Regeneron), stripping management of execution control. ⚖️ 𝐕𝐞𝐫𝐝𝐢𝐜𝐭: ⚪ Neutral. The strategic pivot is complete and execution on GLIX1 has begun. However, an accelerating R&D spend against a strictly capped cash runway creates a high-risk timeline. Unless APHEXDA royalties surge dramatically, financing risk will heavily weigh on the stock over the next 12 months. 𝐊𝐞𝐲 𝐓𝐡𝐞𝐦𝐞𝐬 🟢🟢 𝐆𝐋𝐈𝐗𝟏 𝐄𝐧𝐭𝐞𝐫𝐬 𝐭𝐡𝐞 𝐂𝐥𝐢𝐧𝐢𝐜 [NEW] The company's new crown jewel, GLIX1, officially entered the clinic with the first patient dosed at NYU Langone in March 2026. R&D expenses are accelerating, up 56% YoY to $2.5M, directly reflecting trial initiation costs. The Phase 1 portion will enroll up to 30 patients with recurrent GBM to establish a maximum tolerated dose (MTD) before expanding into newly diagnosed GBM and other cancers. 🔴 𝐙𝐞𝐫𝐨 𝐌𝐚𝐫𝐠𝐢𝐧 𝐟𝐨𝐫 𝐓𝐫𝐢𝐚𝐥 𝐃𝐞𝐥𝐚𝐲𝐬 A concerning contradiction exists between the financial narrative and clinical reality. Management continues to guide for a cash runway into H1 2027 based on $17.4M in reserves. However, early-stage oncology trials frequently experience enrollment delays. If the GLIX1 30-patient Phase 1 trial timeline slips past H1 2027, BioLineRx will hit a funding wall before delivering the proof-of-concept data needed to attract institutional capital. 🟢 𝐀𝐏𝐇𝐄𝐗𝐃𝐀 𝐂𝐨𝐦𝐦𝐞𝐫𝐜𝐢𝐚𝐥 𝐑𝐚𝐦𝐩 Ayrmid's commercial execution with APHEXDA continues to accelerate. Gross sales reached $2.7M in Q1 2026, nearly double the $1.4M generated a year ago. This yielded $0.5M in royalty revenue. While this won't fully fund the $10M-$12M annual burn rate, sustained sequential growth here is the company's best defense against early dilution. 🟢 𝐓𝐡𝐞 𝐇𝐢𝐝𝐝𝐞𝐧 𝐂𝐚𝐭𝐚𝐥𝐲𝐬𝐭: 𝐌𝐨𝐭𝐢𝐱𝐚𝐟𝐨𝐫𝐭𝐢𝐝𝐞 𝐢𝐧 𝐏𝐃𝐀𝐂 While GLIX1 takes center stage, the CheMo4METPANC Phase 2b trial in metastatic pancreatic cancer (PDAC) remains a massive binary event. The trial, evaluating motixafortide in combination with cemiplimab and chemotherapy, is expected to hit its prespecified interim/futility analysis in 2026 when 40% of progression-free survival (PFS) events occur. Positive data here could drastically alter the company's valuation regardless of GLIX1 progress. ⚪ 𝐏𝐀𝐑𝐏 𝐈𝐧𝐡𝐢𝐛𝐢𝐭𝐨𝐫 𝐂𝐨𝐦𝐛𝐢𝐧𝐚𝐭𝐢𝐨𝐧𝐬 [NEW] BioLineRx announced two upcoming ASCO abstracts highlighting compelling mechanistic rationale for combining GLIX1 with PARP inhibitors. Pre-clinical data showed synergistic effects across diverse cell lines, including tumors typically less responsive to PARP inhibition. This lays the groundwork for Phase 2a expansion cohorts. 𝐎𝐭𝐡𝐞𝐫 𝐊𝐏𝐈𝐬 𝐆𝐞𝐧𝐞𝐫𝐚𝐥 & 𝐀𝐝𝐦𝐢𝐧𝐢𝐬𝐭𝐫𝐚𝐭𝐢𝐯𝐞 𝐄𝐱𝐩𝐞𝐧𝐬𝐞𝐬: $0.9 million Stable to decelerating. G&A fell 13.3% YoY from $1.0 million, reflecting the continuing benefits of the company's shift away from commercial infrastructure toward a lean drug-development organization. 𝐍𝐞𝐭 𝐍𝐨𝐧-𝐎𝐩𝐞𝐫𝐚𝐭𝐢𝐧𝐠 𝐈𝐧𝐜𝐨𝐦𝐞: $0.5 million Reversing violently from $7.6 million in Q1 2025. This line item is primarily driven by non-cash fair-value adjustments of warrant liabilities based on share price volatility. Investors should strip this out and focus purely on the $3.0M operating loss. 𝐆𝐮𝐢𝐝𝐚𝐧𝐜𝐞 𝐂𝐚𝐬𝐡 𝐑𝐮𝐧𝐰𝐚𝐲: Into the first half of 2027 Stable. Maintained from prior quarters, backed by $17.4 million in cash and short-term deposits. This implies an average quarterly cash burn of roughly $2.5M to $3.0M going forward. 𝐂𝐡𝐞𝐌𝐨𝟒𝐌𝐄𝐓𝐏𝐀𝐍𝐂 𝐈𝐧𝐭𝐞𝐫𝐢𝐦 𝐀𝐧𝐚𝐥𝐲𝐬𝐢𝐬: 2026 Stable. Management continues to anticipate the 40% PFS event threshold will be crossed this year, providing a crucial interim look at motixafortide's efficacy in pancreatic cancer. 𝐊𝐞𝐲 𝐐𝐮𝐞𝐬𝐭𝐢𝐨𝐧𝐬 𝐂𝐨𝐧𝐭𝐢𝐧𝐠𝐞𝐧𝐜𝐲 𝐟𝐨𝐫 𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐃𝐞𝐥𝐚𝐲𝐬 With the cash runway and the GLIX1 Phase 1 readout both targeted for H1 2027, what proactive financial mechanisms are in place if the 30-patient enrollment takes even one quarter longer than modeled? 𝐀𝐏𝐇𝐄𝐗𝐃𝐀 𝐌𝐢𝐥𝐞𝐬𝐭𝐨𝐧𝐞 𝐕𝐢𝐬𝐢𝐛𝐢𝐥𝐢𝐭𝐲 Given the accelerating commercial sales of APHEXDA by Ayrmid, how close is the company to triggering the first of the potential $87 million in commercial milestones? 𝐏𝐃𝐀𝐂 𝐂𝐨𝐦𝐦𝐮𝐧𝐢𝐜𝐚𝐭𝐢𝐨𝐧 𝐏𝐫𝐨𝐭𝐨𝐜𝐨𝐥 For the upcoming CheMo4METPANC interim analysis in 2026, what is the specific communication protocol with Columbia University? Will BioLineRx be permitted to release detailed PFS data, or just a binary 'continue/stop' outcome?

$BLRX up 4% on earnings day with 145% average volume. ASCO opens Friday. Two GLIX1 abstracts go live to every pharma BD team on the planet. This is how acquisitions start. $AZN $PFE $MRK $BIIB $VRTX #ASCO2026 #biotech #GBM

With GLIX1 abstracts being published at @ASCO on Friday May 29th. Two of the most important days $BLRX has had in years. $GME $HOLO $MRNA $BIIB $VRTX $AZN $PFE $REGN #ASCO2026 #biotech #GBM #oncology #braintumor

Market Wire News @marketwirenews

4 weeks ago

$BLRX - BioLineRx to Report First Quarter 2026 Results on May 27 2026 News & Disclaimer ift.tt/aJRjm2x

0 0 2 331 0

$BLRX BioLineRx presented P0 Glioblastoma results on 2026-05-19 for GLIX-1 More Info: pryzm.ozmosi.com/product/36797

BioLineRx and Hemispherian Announce New GLIX1 Data Demonstrating Potent Anti-Tumor Effect in Glioblastoma (GBM) Across Multiple In-Vivo Studies, Including a Temozolomide (TMZ)-Resistant Model with Patient-Deriv... $BLRX stocktitan.net/news/BLRX/bio-…

$BLRX BioLineRx announced they will present P1 Glioblastoma results in 2H26 for GLIX-1 More Info: pryzm.ozmosi.com/product/36797

$BLRX BioLineRx announced they will present P1 Glioblastoma results in YE27 for GLIX-1 More Info: pryzm.ozmosi.com/product/36797

$BLRX BioLineRx and Hemispherian Announce New GLIX1 Data Demonstrating Potent Anti-Tumor Effect in Glioblastoma (GBM) Across Multiple In-Vivo Studies, Including a Temozolomide (TMZ)-Resistant Model with Patient-Derived Xenografts - Orally administered GLIX1 showed dose-dependent anti-tumor activity in three orthotopic cell-derived xenograft models, with tumor growth inhibition and survival benefit across all doses. - In a new subcutaneous temozolomide (TMZ)-resistant patient-derived xenograft model, GLIX1 produced a robust anti-tumor effect while TMZ showed no effect, supporting the ongoing Phase 1/2a trial in recurrent and progressive GBM and other high-grade gliomas. stocktitan.net/news/BLRX/bio-…

BioLineRx and Hemispherian AS Highlight New Data on GLIX1 at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting $BLRX crweworld.com/article/news-p…

$BLRX just dropped two abstracts at ASCO 2026. First-in-class brain cancer drug. 68-85% blood-brain barrier penetration. Works where nothing else does. TMZ-resistant patients finally have hope. $MRNA $BIIB $VRTX $AZN $PFE $REGN #ASCO2026 tipranks.com/news/company-a…

@HunterAllen4 $BLRX on the rise again, with close to zero retail interest on Twitter or Reddit. Institutions are loading up. @biotechstockbot @BiotechWorld @MarketWatch 👀

$BLRX pancreatic cancer pilot data alone showed 64% response rate vs 23% historical. Two patients had complete responses. GLIX1 could unlock PARP inhibitors for 94% of all cancers. First patient dosed last week. $MRNA $BIIB $VRTX $REGN $AZN $PFE ir.biolinerx.com

First patient in human history dosed in the GLIX1 glioblastoma trial today. Led by Dr. Roger Stupp, who wrote the current standard of care for GBM in 2005. Three world class cancer centers enrolling patients. $BLRX Phase 1 data expected H1 2027. Worth knowing about. $MRNA $BIIB

stock setter @MarcJacksonLA

2 months ago

$BLRX BioLineRx and Hemispherian Announce First Patient Dosed in Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM) - Data from the Phase 1 part of the study anticipated in H1 2027 stocktitan.net/news/BLRX/bio-…

0 0 3 373 0

BiolineRx $BLRX is on the verge of curing cancer. $GME $HOLO $AMC 🚀 🌕

BioLineRx and Hemispherian Announce First Patient Dosed in Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM) $BLRX stocktitan.net/news/BLRX/bio-…

AM / PM earnings calendar breakdown (week of Mar 23, 2026) 📅 MONDAY (MAR 23) 🌅 Before Open Lithium Arg $BLRX WeRide $WRD 🌙 After Close Public Policy Holding Company $PPHC Bionano Genomics $BNGO AGI (likely Alamos Gold depending on listing context) 👉 Mostly small-cap biotech + lithium sentiment reads 📅 TUESDAY (MAR 24) 🌅 Before Open Achieve Life Sciences $ACHV Vertical Aerospace $EVTL Core & Main $CNM Sanara MedTech $SMTI 🌙 After Close Braze (BRZE) Noah Holdings (NOAH) AAR Corp. $AIR Absci $ABSI MaxCyte $MXCT BioStem Technologies $BCDA 👉 Key watch: Braze (AI marketing SaaS signal) 📅 WEDNESDAY (MAR 25) ⭐ BIGGEST DAY 🌅 Before Open Ondas Holdings $ONDS Chewy $CHWY PDD Holdings $PDD Cintas $CTAS Paychex $PAYX Baozun $BZUN Cognite $CGNT Viomi Technology (VIOT) 🌙 After Close Beyond Meat $BYND GCT Semiconductor $GCTS Dermira $DERM Dyadic International $DYAI Enerpac Tool Group $EPAC CaliberCos $CWD Cyngn $CYN 👉 Macro signals here: Chewy = consumer resilience Paychex = labor market health PDD = China + Temu global pricing pressure 📅 THURSDAY (MAR 26) 🌅 Before Open PAVmed $PAVM Pony.ai $PONY Commercial Metals Company $CMC Lovesac $LOVE Quoin Pharmaceuticals $QNIX Designer Brands $DBI Lucid Diagnostics $LUCD 🌙 After Close Veritone $VERI Blink Charging $BLNK Alpha Cognition $ACOG Westport Fuel Systems $WPRT BitGo $BitGo Newsmax $NMAX Oxford Industries $OXM Argan $AGX 👉 Key watch: Veritone = AI enterprise demand proxy 📅 FRIDAY (MAR 27) ⭐ TRAVEL SIGNAL DAY 🌅 Before Open Carnival Corporation $CCL Autolus Therapeutics $AUTL TimkenSteel $TMC SBC Medical Group Holdings $SBC Legence $LGN Super League Enterprise $SLE 👉 Carnival is the largest macro consumer signal this week (travel demand + fuel cost sensitivity). 🎯 TOP 5 REPORTS MOST LIKELY TO MOVE MARKETS Ranked by volatility + macro importance: 🥇 PDD 🥈 Chewy 🥉 Carnival 4️⃣ Paychex 5️⃣ Beyond Meat

$BLRX - BioLineRx Announces Initiation of Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM)

$BLRX to report 2035 Annual Results next Monday March 23rd 2026 ir.biolinerx.com/news-releases/…

BioLineRx Wins Arbitration Ruling in Motixafortide Licensing Dispute $BLRX tipranks.com/news/company-a…